[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-330010-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-330010-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","senate-bill-418-prescription-hormone-therapy-and-nondiscrimination-abbreviated-analysis","Senate Bill 418 - Prescription Hormone Therapy and Nondiscrimination - Abbreviated Analysis","","Abbreviated Analysis prepared for the 2025–2026 California State Legislature evaluates California Senate Bill 418 on prescription hormone therapy and nondiscrimination. The analysis would require state-regulated health plans to cover up to a 12-month supply of FDA-approved prescription hormone therapy and related self-administration supplies, under defined dispensing and provider conditions. CHBRP projects limited utilization shifts, with small budget impact ($476,000 net annual expenditures increase, \u003C0.01%) and potential reductions in access barriers and improved quality of life for some patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/senate-bill-418-prescription-hormone-therapy-and-nondiscrimination-abbreviated-analysis/330010/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/senate-bill-418-prescription-hormone-therapy-and-nondiscrimination-abbreviated-analysis/330010.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What would SB 418 require regarding prescription hormone therapy coverage?","Question",{"text":63,"@type":64},"SB 418 would require health plans and policies to cover up to a 12-month supply of FDA-approved prescription hormone therapy and the necessary supplies for self-administration, as prescribed by a network provider within scope of practice.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who would be affected by SB 418 in 2026?",{"text":68,"@type":64},"In 2026, 23.5 million Californians (61.8% of all Californians) enrolled in state-regulated health insurance would have insurance subject to SB 418.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the projected cost and health impacts according to CHBRP?",{"text":72,"@type":64},"CHBRP estimates SB 418 would increase total net annual expenditures by $476,000 (\u003C0.01%) in 2026. While broader public health impacts may affect few people, receiving 12 months at once could reduce access barriers and improve quality of life for some people.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},330010,1790484753,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Abbreviated Analysis  \nCalifornia Health Benefits Review Program (CHBRP), University of California, Berkeley  \n[chbrp.org](chbrp.org)  \nCalifornia  \nSenate Bill 418:  \nPrescription Hormone Therapy and  \nNondiscrimination  \nReport to the 2025–2026 California State Legislature  \nAUGUST 14 , 2025  \nKEY FINDINGS  \nAbbreviated Analysis of California Senate Bill 418 Prescription Hormone Therapy and Nondiscrimination  \nSummary to the 2025–2026 California State Legislature, August 14, 2025  \nSummary  \nThe version of California Senate Bill (SB) 418 analyzed by California Health Benefits Review Program (CHBRP) would require health plans and policies to cover up to a 12-month supply of a U.S. Food and Drug Administration-approved prescription hormone therapy and the necessary supplies for self-administration. SB 418 would allow an enrollee to receive a covered hormone therapy, prescribed by a network provider and dispensed by a provider or pharmacist or at a location licensed or otherwise authorized to dispense drugs or supplies, for up to 12 months at one time.  \nIn 2026, 23.5 million Californians (61 .8% of all Californians) enrolled in state-regulated health insurance would have insurance subject to SB 418.  \nBenefit Coverage  \nWhile SB 418 would be unlikely to create a measurable number of new users due to broad baseline coverage of hormone therapies, CHBRP estimates that 0.09% of enrollees with health insurance subject to SB 418 would switch to a 12-month supply.  \nCost and Health Impacts1  \nIn 2026, SB 418 would lead to an increase in total net annual expenditures of $476,000 (\u003C0 .01%) .  \nAlthough public health impacts of SB 418 are likely to affect a small number of people, CHBRP anticipates that receiving 12 months of hormone therapy at once could reduce barriers to accessing treatment and improve quality of life for some people.  \n1 Similar cost and health impacts could be expected for the following year, although possible changes in medical science and other aspects of health make stability of impacts less certain as time goes by.  \nContext  \nPer California state law, dispensing of “dangerous drugs”  \n– which includes those that are labeled “rx only” – is limited to 90 days.2 SB 418 would allow for longer durations of hormone therapy to be dispensed at once.  \nHormone therapy is used in the treatment of several diseases and conditions to medically suppress, block, increase, or replace hormones that the body is not producing at intended levels. CHBRP’s analysis of SB 418 discusses the following conditions for which hormone therapy is commonly used: menopause, breast cancer, prostate cancer, gender dysphoria and gender incongruence, hypothyroidism, and thyroid cancer. Hormone therapy may be used in the course of treatment for additional conditions not in the Background section of this analysis; however, all uses of hormone therapy are considered in the Benefit Coverage, Utilization, and Cost Impacts section.  \nBill Summary  \nCHBRP was requested to analyze sections 4, 5 , and 7 of SB 418 as amended on July 9, 2025, which would:  \n• Require health plans and policies to cover up toa 12-month supply of a U.S. Food and Drug Administration (FDA)-approved prescription hormone therapy, as well as the necessary supplies for self-administration, as prescribed by a network provider within their scope of practice;  \n• Allow an enrollee to receive a covered hormone therapy, dispensed by a provider or pharmacist, or at a location licensed or otherwise authorized to dispense drugs or supplies, for up to 12 months at one time;  \n• Allow – but not require – a provider to prescribe, furnish, or dispense 12 months of prescription hormone therapy at one time;  \n• Prohibit the use of utilization management or other forms of medical management to limit a  \n2 BPC 4064.5, BPC 4022.  \nCurrent as of August 14, 2025  [chbrp.org](chbrp.org)  \nKey Findings: Abbreviated Analysis of California Senate Bill 418  \n12-month supply of an FDA-approved prescription ","cbCairiRsZMB0BOU","https://ap.wps.com/l/cbCairiRsZMB0BOU","pdf",1416599,57,"English","# Summary\n## Benefit Coverage\n## Cost and Health Impacts\n# Context\n## Bill Summary\n## How does utilization impact premiums?","[{\"question\":\"What would SB 418 require regarding prescription hormone therapy coverage?\",\"answer\":\"SB 418 would require health plans and policies to cover up to a 12-month supply of FDA-approved prescription hormone therapy and the necessary supplies for self-administration, as prescribed by a network provider within scope of practice.\"},{\"question\":\"Who would be affected by SB 418 in 2026?\",\"answer\":\"In 2026, 23.5 million Californians (61.8% of all Californians) enrolled in state-regulated health insurance would have insurance subject to SB 418.\"},{\"question\":\"What are the projected cost and health impacts according to CHBRP?\",\"answer\":\"CHBRP estimates SB 418 would increase total net annual expenditures by $476,000 (\\u003c0.01%) in 2026. While broader public health impacts may affect few people, receiving 12 months at once could reduce access barriers and improve quality of life for some people.\"}]","Senate Bill 418 - Prescription Hormone Therapy and Nondiscrimination - Abbreviated Analysis | PDF",1789986531,144]